Insurance Plans Vary in Coverage of Gender-Affirming 'Top' Surgery for Transgender Patients
Insurance companies having variable policies for covering gender-affirming breast/chest "top" surgery in transgender patients, according to a special topic paper in the October issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS).
"Our survey study finds marked variation in policy criteria for top surgery between insurers," comments lead author Yvonne Marsha Rasko, MD, of University of Maryland School of Medicine, Baltimore. "These criteria often deviate from established global recommendations, and some insurers categorically deny access to gender-affirming top surgery."
Insurers Have Inconsistent Criteria for Covering Transgender Breast/Chest Surgery
Gender-affirming surgery refers to medically necessary reconstructive procedures performed to treat gender dysphoria, as outlined in the evidence-based standards of care developed by the World Professional Association for Transgender Health (WPATH). Often the first and sometimes only form of surgery undertaken by patients in transition is top surgery: bilateral mastectomy (masculinizing chest surgery) in transgender men and breast augmentation (feminizing chest surgery) in transgender women.
Both forms of top surgery improve quality of life and reduce symptoms of gender dysphoria in transgender individuals. With recent cultural shifts and legislative mandates, the medical necessity of these procedures is now widely acknowledged – yet many patients are still denied insurance coverage for transition-related reconstructive surgery.
Dr. Rasko and colleagues evaluated variability in insurance coverage and policy criteria for gender-affirming breast/chest surgery. The researchers analyzed coverage status from 57 US insurance companies, only one of which had no relevant policy on these procedures.
Fifty-three of the 57 insurance companies provided coverage for gender-affirming top surgery, after preauthorization. Two companies provided coverage on a case-by case basis; one provided no coverage. Only two insurers had criteria consistent with WPATH recommendations.
The survey revealed discrepancies in coverage for the two types of top surgery. While 96 percent of insurance companies covered bilateral mastectomy/masculinizing surgery in transgender men, only 68 percent covered breast augmentation/feminizing surgery in transgender women. "The insurers that did not provide coverage for transfeminine breast surgery listed the procedure as 'not medically necessary,'" the researchers write.
Nearly all had companies had general criteria for covering masculinizing chest surgery, but only about half had similar criteria for preapproval of feminizing breast surgery. Many insurers had additional criteria that were inconsistent with WPATH standards, such as time living in a congruent gender role, preceding hormone therapy, and evaluation by multiple mental health professionals.
"We have highlighted the great variability in coverage and medical necessity criteria for gender-affirming top surgery across insurance companies," Dr. Rasko and coauthors conclude. "We hope to encourage greater uniformity between insurance companies in regard to their policy criteria, in addition to empowering both patients and surgeons with the information to enable them to advocate for treatment in this underserved population."
In a video commentary on the Plastic and Reconstructive Surgery website, ASPS Member Surgeon Loren Schechter, MD, comments: "The authors highlight many of the challenges and inequities associated with insurance policies pertaining to medically necessary care in the transgender and gender-diverse community." Dr. Schechter adds, "Additional studies are required to bolster the preponderance of medical evidence supporting gender-affirming medical and surgical care."
Click here to read "Health Insurance Coverage of Gender-Affirming Top Surgery in the United States"
Article: "Health Insurance Coverage of Gender-Affirming Top Surgery in the United States" (doi: 10.1097/PRS.0000000000006012)
About Plastic and Reconstructive Surgery
For more than 70 years, Plastic and Reconstructive Surgery® has been the one consistently excellent reference for every specialist who uses plastic surgery techniques or works in conjunction with a plastic surgeon. The official journal of the American Society of Plastic Surgeons, Plastic and Reconstructive Surgery® brings subscribers up-to-the-minute reports on the latest techniques and follow-up for all areas of plastic and reconstructive surgery, including breast reconstruction, experimental studies, maxillofacial reconstruction, hand and microsurgery, burn repair, and cosmetic surgery, as well as news on medico-legal issues.
The American Society of Plastic Surgeons (ASPS) is the world's largest organization of board-certified plastic surgeons. Representing more than 8,000 member surgeons, the Society is recognized as a leading authority and information source on aesthetic and reconstructive plastic surgery. ASPS comprises more than 93 percent of all board-certified plastic surgeons in the United States. Founded in 1931, the Society represents physicians certified by The American Board of Plastic Surgery or The Royal College of Physicians and Surgeons of Canada. ASPS advances quality care to plastic surgery patients by encouraging high standards of training, ethics, physician practice and research in plastic surgery.
About Wolters Kluwer
Wolters Kluwer is a global leader in professional information services. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.
Wolters Kluwer reported 2015 annual revenues of €4.2 billion. The group serves customers in over 180 countries, and employs over 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).
Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. For more information about our products and organization, visit www.wolterskluwer.com, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.